Tumor Microenvironment in Ovarian Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-80
SponsorUniversity of Udine
About this trial
A detailed understanding of molecular mechanism of cancer genesis is fundamental to develop innovative and personalized therapies. The new frontier in biomedical research is represented by organoids, a three-dimensional cell culture system obtained from a tissue fragment that accurately reproduces the essential properties of the original tissue in vitro, which could provide a valuable model for explanation of ovarian cancers pathogenesis and will allow to predict the response to a specific therapy. With this research project, we expect to generate ovarian cancer organoids to characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age > 18 years
Age < 80 years
Serous ovarian carcinoma
FIGO Stage III-IV
Disqualifiers
Ongoing or suspended immunosuppressive therapy within the last 6 months
Congenital or acquired immunodeficiency
Immunosuppressive state
Administration of chemotherapy for another neoplasm in the past 12 months
Trial population
Patients with primary diagnosis (t=0) of epithelial ovarian cancer (stage III and IV according to FIGO)
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Ovarian Cancer Organoids
Other interventionTo characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules)
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
• Composition of the tumor microenvironment (including the immune system and intratumoral microbiota). • Generate organoids
Characterize the composition of the tumor microenvironment (including the immune system and intratumoral microbiota). Generate organoids from cells derived from ovarian tissue.
Time frame
from enrollment to the end of follow up at 36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov